Results 161 to 170 of about 25,814 (203)

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry. [PDF]

Oncologist
Passiglia F, Reale ML, Pasello G, Viscardi G, Attili I, Mazzoni F, Galetta D, Catania C, Andrikou K, Russo A, Vavala T, Bulotta A, Calvetti L, Carta AM, Grisanti S, Mariotti S, La Cava G, Dodi A, Scotti V, Del Giudice T, Minuti G, Pizzutillo EG, Chiari R, Della Corte CM, Genova C, Lo Russo G, Pignataro D, Pozzessere D, Roca E, Toschi L, Bennati C, Borra G, Bettini A, Favaretto A, Gelibter A, Gori S, Tabbò F, Pagano M, Pavan A, Belluomini L, Tondulli L, Sergi C, Stanzione B, Malapelle U, Novello S, Bria E.   +45 more
europepmc   +1 more source

Nuevas Perspectivas en Oncología Médica y Quirúrgica

Nicole Elizabeth Puga Miranda, Myriam karina Solis Mora, Joselyn Andrea Canelos Moreno, Diana Yamilec Brito Solano   +3 more
openalex   +1 more source

Correction: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. [PDF]

Oncotarget
Belli V, Sforza V, Cardone C, Martinelli E, Barra G, Matrone N, Napolitano S, Morgillo F, Tuccillo C, Federico A, Dallio M, Loguercio C, Gravina AG, Palma R, Ciardiello F, Troiani T.   +15 more
europepmc   +1 more source

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study. [PDF]

ESMO Gastrointest Oncol
Trovato G, Carullo M, Nicastro A, Spoto C, Perissinotto E, Giordano G, Di Giacomo E, Calegari MA, Pasquinucci V, Troiani T, Tamberi S, Schirripa M, Scartozzi M, Morano F, Arrivi G, Morelli C, Basso M, Landi M, Martinelli E, Zoratto F, Bergamo F, Landriscina M, Lucchetti J, Cremolini C, Tortora G, Salvatore L.   +25 more
europepmc   +1 more source

[Pathological anatomy and its importance in the hospital setting]. [PDF]

Rev Med Inst Mex Seguro Soc
Dragustinovis-Valdez IY, Naranjo-Baltazar P.   +1 more
europepmc   +1 more source

Water pollution and childhood leukaemia risk: a systematic review. [PDF]

Ecancermedicalscience
Nuñez-Enriquez JC, Medina-León D, Tinoco-Montejano D, Jacuinde-Trejo K, Flores-Lujano J, Gómez-Rivera L, Chávez-Martínez O, García-Alvarado FJ, Blanco-Padilla P, Pelayo R.   +9 more
europepmc   +1 more source

Pathway from lichen sclerosus to squamous cell carcinoma of the penis: the oncologist's perspective. [PDF]

Urol Case Rep
Couto M, Oura MJ, Tavares NT, Barbosa M, Pereira P, Pinto R, Augusto I.   +6 more
europepmc   +1 more source

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> 2021, <i>13</i>, 6256. [PDF]

Cancers (Basel)
Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, Hernández-Pedro NY, Ortega-Gómez A, Lara-Mejía L, Rangel-Escareño C, Arrieta O.   +14 more
europepmc   +1 more source

Correction: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). [PDF]

Clin Transl Oncol
Alsina Maqueda M, Teijo Quintáns A, Cuatrecasas M, Fernández Aceñero MJ, Fernández Montes A, Gómez Martín C, Jiménez Fonseca P, Martínez Ciarpaglini C, Rivera Herrero F, Iglesias Coma M.   +9 more
europepmc   +1 more source

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors. [PDF]

Sci Rep
Torrisi R, Giordano L, Pancetti S, Carnaghi C, Basilico V, Palumbo R, Gerosa R, Saltalamacchia G, Sanò MV, Santoro A, Fernandes B.   +10 more
europepmc   +1 more source